Loading company
NeuroPace Inc
NPCE · Nasdaq · ·
Next earnings: November 3, 2026
$13.97-1.3%Sep 29 close
- 1M
- -3.1%
- 6M
- +8.8%
- 1Y
- +35.5%
- 5Y
- -13.6%
NeuroPace Inc is the 59th largest of 132 graded companies. Showing 5 of them, including NPCE itself. 11 more are in this industry but have no grade yet, so they are left out rather than shown blank.
| Company | Grade | Market value | Revenue | Profit margin | Free cash flow | Price to earnings |
|---|---|---|---|---|---|---|
| Abbott LaboratoriesABT | B+ | $175.9B | $45.1B | 13.9% | $7.4B | 28.20 |
| Medtronic plcMDT | A+ | $111.4B | $37.5B | 13.9% | $6.1B | 21.40 |
| Stryker Corp.SYK | A+ | $107B | $25.8B | 14.4% | $4.7B | 28.90 |
| Boston Scientific CorporationBSX | B+ | $63.6B | $21B | 17.5% | $3.6B | 17.77 |
| Neuropace, Inc.NPCE | D- | $479.5M | $98.8M | -19.3% | -$11.6M | — |
127 more medical devices companies
Graded on the same five checks, from their own SEC filings.
A blank price-to-earnings means a loss, not a missing figure — the ratio has no meaning when there are no earnings to divide by, and printing a negative one would make the least profitable company look the cheapest.
Grades are trailing twelve months from each company’s own SEC filings, so they move only when a company files. Every column is computed by the same code that graded NeuroPace Inc on the overview — nothing here comes from a data vendor’s own ratios.
Industry membership is not a judgement about how similar two businesses are. It groups companies by what they are classified as, which is a starting point for comparison rather than a claim that they compete.
NPCE · Nasdaq · ·
Next earnings: November 3, 2026
$13.97-1.3%Sep 29 close